About Us

Meet Our Team



Max Narovlyansky

Max Narovlyansky, PhD

Founder and CEO

Expert in microfluidics

Experienced in drug discovery and companion diagnostics.

maxn@flowcell.co

Max’s early research focused on microfluidic technologies addressing the fact that pre-analytics is the limiting factor in biological research and medical treatment. Specifically, electrokinetic manipulation of cells and protein is a novel but highly efficient tool. He has shown it to be applicable to capture and lysis of cells and extremely rapid resolution of proteins. One of his contributions described using the similitude condition between electric field and flow of charged species, which allowed precise shaping of molecular distribution for enhanced diagnostic separation. Other work has focused on the sensors, including the incorporation of optical and electrochemical elements in traditional and paper-based microfluidics. Other microfluidic applications have involved creative use of reactive flows, including in situ reduction reactions for micropatterning of films.

Lahiri K. Nanduri

Lahiri K. Nanduri, PhD

CSO

Expert in micro-physiological systems

Established 3D in vitro stem cell cultures, testing disease models.

lahirin@flowcell.co

Lahiri Nanduri is a biologist with over 15 years of expertise in single-cell methods for oncology. He has lots of publications known as an SME in this field. Lahiri has worked in multiple organizations with organoids, biobanking, and evaluating cutting-edge tools.

Mark Wesson

Mark Wesson, MPH, FACHE

CFO

Healthcare innovator

Expert in biotech startup financial planning.

markw@flowcell.co

Mark Wesson has experience leading analysis and restructuring of the programs to improve the quality of care for patients. He’s also skilled at cultivating innovation using the latest technologies to improve information management and communication. Over his 20-year career, Mark has designed, conducted, managed, analyzed, or reported many health care projects.

He has disseminated many of the resulting data-driven program proposals and reports directly to providers or senior health care executives. Mark worked with providers, executives, and support staff across the continuum of care within the emergency, inpatient, and outpatient care delivery settings. He simultaneously project managed, coordinated, or consulted on analytic, strategic, financial, operational, or system administration responsibilities.

Dr.S.S.R Kumar Challa

Dr.S.S.R Kumar Challa

Board Member (Director)

Expert in nanotechnology and startup entrepreneurship.

Contributed to 80 scientific publications, 12 patents, and edited 34 books and 2 journals relating to nanotechnology. 

S.S.R. Kumar Challa has over 20 years of experience in nanotechnology research within the academic and start-up arenas. While taking a break from academic research, he is focusing primarily on start-ups. He recently completed an assignment as the Managing Director at Harvard University’s Energy Frontier Research Center in Cambridge, Massachusetts, and Director of Nanomaterials at the Center for Advanced Microstructures & Devices (CAMD) at LSU in Baton Rouge, Louisiana.

Alan K. Hauser

Alan K. Hauser, PhD, MBA

COO

Expert in strategic commercial development

Built 9 biotech businesses, including a Silicon Valley microfluidic startup’s $189 million IPO.

Alan K. Hauser is a PrecisionCare executive championing life-sciences Innovation-to-Commercialization (I2C) by translating the promise of emerging proprietary multi-omic platforms into practice. Dr. Hauser has over three decades of experience in technical, intellectual, property, market, and business development aspects of commercializing drug-discovery and diagnostics inventions. 

Dr. Hauser co-invented four U.S. patents covering microfluidic bio tools and launched nine drug-discovery and DNA diagnostic products. This resulted in two initial public offerings that include a Silicon Valley lab-on-a-chip venture of $180 million IPO. Five of these companies have acquired totaling over $1.8 billion. Dr. Hauser led an I2C team that focused on biomarker-enabled companion diagnostics acquiring $150 million of IP-powered revenue per year. His experience in stratified medicine is particularly relevant to the mission of FlowCell and Fluids for Life.

Umer Sayeed-Shah

Umer Sayeed-Shah, MD FACS FAHA

Capital Management Leader

Expert in capital management, bio-techbology, and cardiovascular medicine.

Harvard cardiac surgeon with expertise in gene therapy, laser-termolysis, tissue engineering.

Dr. Umer Sayeed-Shah brings his expertise in finance and the capital markets, cardiovascular medicine, and bio-medical science to Flow Cell.

Dr. Shah is a leading cardiovascular surgeon and scientist. He is a graduate of Boston University School of Medicine. He completed his Residency in Cardiovascular and Thoracic Surgery at Yale University. He completed both his Research Fellowship and Clinical Fellowship in Cardiovascular Surgery at Harvard University and the Brigham and Women’s Hospital. He was trained in the laboratories and under the mentorship of Dr. Lawrence H Cohn, in the Division of Cardiac Surgery, and Dr. Victor Dzau in the Division of Cardiology and Molecular Medicine at Harvard Medical School.

Dr. Shah is a pioneer in laser-thermolysis, gene therapy, tissue engineering, and cell reprogramming. He has received international recognition through numerous awards and academic honors for his clinical and scientific expertise and for the development of novel methodologies in both minimally invasive surgery and molecular medicine. Among these are the American Association for Thoracic Surgery First Annual C. Walton Lillehei Award, the American College of Cardiology Young Investigator Award in Molecular and Cellular Cardiology, the American Heart Association Travel Fellowship, and the Medtronic Award at Harvard Medical School. He is the recipient of patents from both the United States and the European Union relating to basic and translational methodologies and applications in gene therapy, minimally-invasive surgery, and laser surgery.

Dr. Shah has previously served as an Instructor in Surgery at Yale University, Assistant Professor of Surgery at Boston University, and Director at the Harvard Center for Minimally Invasive Surgery. He is a diplomate of the American Board of Surgery, American Board of Thoracic Surgery, and of the American Heart Association Council on Cardiothoracic and Vascular Surgery.

Dr. Shah is the founder of BostonInformatix, LLC, a Cambridge - based market analytics firm, and is the inventor of the broadly referenced AI-based, algorithmic trading platform, the SuperIndexTM. He is at present a principal of Roe Capital Management, LLC, and has a keen interest in mentoring and guiding biotechnology firms.